Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Window of Opportunity Trial of Ipilimumab and Nivolumab in Metastatic Recurrent HER2- Inflammatory Breast Cancer (IBC) The Win Trial

NCT02892734 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT02892734
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02892734 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Window of Opportunity Trial of Ipilimumab and Nivolumab in Metastatic Recurrent HER2- Inflammatory Breast Cancer (IBC) The Win Trial
Lead sponsor
Northwestern University
Phase
Phase 2
Overall status
Terminated
Start date
September 18, 2017
Completion date
February 4, 2019
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2/neu negative, recurrent inflammatory breast carcinoma, stage iv breast cancer, stage iv inflammatory breast carcinoma